Corporate GovernanceApr 29, 2026, 04:38 PM
ELTX Amends 10-K for Board & Executive Officer Details
AI Summary
Elicio Therapeutics, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025. The amendment primarily includes information required by Part III, detailing the company's directors, executive officers, and corporate governance practices, which was intentionally omitted from the original filing. It also updates the exhibit list and includes new certifications. The company's market value of non-affiliate voting stock was approximately $81.8 million as of June 30, 2025.
Key Highlights
- ELTX filed Form 10-K/A to include Part III information on Directors, Executive Officers, and Corporate Governance.
- Robert Connelly serves as President, Chief Executive Officer, and Director.
- Preetam Shah, Ph.D. is Chief Strategy and Financial Officer and Treasurer.
- Christopher Haqq, M.D., Ph.D. is Executive Vice President, Head of R&D, and Chief Medical Officer.
- Peter DeMuth, Ph.D. is Chief Scientific Officer.
- Julian Adams, Ph.D. serves as Chair of the Board of Directors.
- 5 out of 7 non-employee directors are determined to be independent per Nasdaq listing standards.
- Aggregate market value of non-affiliate voting stock was approximately $81.8M as of June 30, 2025.
Price Impact
More from ELTX